[Featured Stock] Alteogen, strengthened after being selected as a Nasdaq preferred stock in May... Looking forward to Keytruda SC growth

Altogen Gene was selected by the securities industry as a May preferred biotech stock on Kosdaq, showing strong momentum. The current share price is 373k KRW, up 4,500 KRW (1.22%) from the previous trading day.

According to securities industry sources, the Korean pharmaceutical and biotech sectors are currently in a short-term adjustment phase due to overlapping delays in the release of complex clinical data and postponements of major events. The disclosure of complex clinical data by the partner company of Eibel Bio, as well as factors such as the delayed release of MASH treatment drug data by Hanmi Pharmaceutical, have to some extent dampened investor sentiment.

However, Altogen Gene is assessed as a target that combines both performance and commercialization expectations. Shinhan Securities noted MSD Curoveda SC’s sales increased 266% quarter-over-quarter, and there is potential for prescription expansion that may come from the activation of U.S. insurance claims coding. In addition, the launch of hyaluronidase monotherapy injections into the global market, as well as the submission of marketing authorization application filings for the biosimilar of aflibercept both domestically and internationally, are also seen as new growth drivers.

The industry’s relatively high development risk has also been highlighted again. According to IQVIA’s 2025 statistics, the success rate from Phase 1 clinical trials to final approval application is only 7%. Therefore, market analysts believe that compared with simply anticipating outcomes, a selective layout is needed around companies whose technology transfer performance and commercialization visibility have already been confirmed.

Previously, since 2022, as listing thresholds for special-case technology have been raised, the quality of newly listed biotech companies has also improved. During this adjustment period, the market appears to be once again focusing on targets with substantive fundamentals and potential for revenue expansion.

Source: Korea Exchange and compiled reports from securities firms